Cipla unit gets 345 million rand contract from South Africa
Cipla Medpro, the South African subsidiary of the Indian firm, has been awarded a 345 million rand share of the South African government’s national respiratory tender, the company said in a statement.
Under the contract, which will run from July 2014 to April 2017, the company will supply drugs including Beclate 100, Becalate 200 and Asthavent 200.
“This is the second-largest government tender awarded to Cipla in the last three years,” the company said.
Cipla Medpro CEO Paul Miller said patients across South Africa will benefit from increased access to Cipla’s respiratory programmes and products.
“This successful tender is yet again testament to the Cipla team’s commitment to excellence and quality and the company ethos of advancing healthcare for all,” he added.
Last year, Mumbai-based Cipla completed the buyout of Cipla Medpro for an aggregate consideration of Rs 2,707 crore.
Cipla Medpro is the third-largest South African pharmaceutical company founded in 1993.